Improving Lives: Breakthroughs & Collaborations - Research Report on Pfizer, Merck, Bristol-Myers Squibb, J&J and Lilly

Mon Mar 18, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

NEW YORK,  March 18, 2013  /PRNewswire/ --

Today, Wall Street Source announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK), Bristol Myers Squibb Co. (NYSE:
BMY), Johnson & Johnson (NYSE: JNJ) and Eli Lilly & Co. (NYSE: LLY). Today's
readers may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

New trial results show promising results for Inspara (eplerenone) in patients
with acute STEMI without heart failure. In randomized, double-blind REMINDER
trial involving 1, 012 patients with acute ST-segment elevation myocardial
infarction (STEMI) without a history of HF or EF,  eplerenone  improved the
outcome of the patients within first 24 hours of symptoms. Adding  eplerenone 
to standard therapy as early as within the first 24hours of symptoms reduced
heart failure-related morbidity. The REMINDER trial demonstrated a statistically
significant 42.9% relative risk reduction in the primary endpoint with p <
0.0001 (95% confidence interval [CI] 0.439, 0.742) in patients with acute STEMI
when  eplerenone  was initiated within the first 24 hours of onset of symptoms.
Overall, the adverse events reported in the REMINDER trial were consistent with
those already known for  eplerenone, primarily hyperkalemia. This should bring
good news to patients who want treatment with higher efficacy but with lower
risks. The Full Research Report on Pfizer Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free of
charge at: []


Merck & Co., Inc. Research Report

A collaboration between Merck and Luminex Corporation is leading to development
of a companion diagnostic device that will be evaluated to help support patient
selection for the clinical development of MK-8931, Merck's lead investigational
medicine for Alzheimer's disease. MK-8931 is a novel oral beta amyloid precursor
protein site cleaving enzyme (BACE) inhibitor. "Evaluation of biomarkers that
may provide an indicator of disease onset and enable earlier diagnosis is an
important goal toward facilitating early intervention and potentially improving
the treatment of Alzheimer's disease," said  Darryle D. Schoepp, Ph.D., senior
vice president, head of Neuroscience and Ophthalmology at Merck Research
Laboratories. "We look forward to working with Luminex to advance our ongoing
clinical development program for MK-8931." Luminex, on the other hand, will be
responsible for development, regulatory submission and commercialization of the
candidate companion diagnostic device. The Full Research Report on Merck & Co.,
Inc. - including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Bristol Myers Squibb Co. Research Report

Grants totaling  $175,000  was awarded to both the American Cancer Society
Eastern Division and Princeton HealthCare System (PHCS) to support comprehensive
navigation services for patients with cancer both independently and as part of a
collaborative effort among several hospitals in central  New Jersey. Navigation
is now viewed as an integral part of cancer services, with several studies
linking patient navigation to improved patient outcome and survival rates.
Navigators help coordinate patients' care and guide them to resources that can
provide psychosocial support and address financial concerns, language or
cultural issues and day-to-day needs such as transportation. "Bringing together
organizations with common goals, similar programs and potentially complimentary
services can lead to efficiencies in immediately tangible ways," says  Murdo
Gordon, SVP-Oncology, U.S. Pharmaceuticals, Bristol-Myers Squibb. "With the
coming changes of the Affordable Care Act, the financial impact on organizations
and individuals will likely be profound, and the entire cancer community will
need to work together to address these concerns. Collaborative approaches, such
as those being taken by UMCPP and the American Cancer Society, which bring
together meaningful services from various providers to support a given
community, is a refreshing solution." The Full Research Report on Bristol-Myers
Squibb Co. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Johnson & Johnson Research Report

Johnson & Johnson is proud to announce the opening of the Johnson & Johnson
Innovative Center in  London, one of the regional hubs being established this
year in the world's leading innovation hotspots. The  London  innovation center
aims to accelerate the best early stage science in the world and advance the
development of new healthcare solutions "Britain  has a worldwide reputation for
excellence in innovation - the investment by Johnson & Johnson here demonstrates
this and I am delighted to welcome this new center to the UK," says UK Secretary
of State for Health  Jeremy Hunt, who will be speaking at the Innovation Expo
2013. Johnson & Johnson Chief Scientific Officer and Worldwide Chairman,
Pharmaceuticals,  Paul Stoffels, MD, says, "The London Innovation Centre is part
of Johnson & Johnson's broader innovation strategy to advance human health
through collaboration with the world's leading scientists and entrepreneurs.  We
are looking forward to collaborating within the UK, home to one of the world's
thriving life sciences ecosystems."  Similar facilities are also being planned
in  Boston,  San Francisco  and, later this year,  Shanghai. Each city was
selected for its robust life sciences community. The Full Research Report on 
Johnson & Johnson - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Eli Lilly & Co. Research Report

Eli Lilly & Co., along with Kowa Pharmaceuticals America, Inc. is pleased to
announce the results of a study evaluating the efficacy of LIVALO (pitavastatin)
4mg compared with  pravastatin  40mg in reducing low-density lipoprotein
cholesterol (LDL-C) in HIV-infected adults with high cholesterol or
dyslipidemia. The study was designed as a superiority trial for the primary
endpoint, percent reduction in LDL-C, and evaluated HIV-infected adults with
dyslipidemia; with and without viral Hepatitis B or C. Dyslipidemia is common in
people with HIV infection and HIV-infected adults are at a greater risk for
cardiovascular disease due to many factor, including lipid abnormalities.
Results showed that, after 12 weeks of therapy,  pitavastatin  had a
significantly greater decrease in LDL-C compared with pravastatin (pitavastatin 
-49.4 mg/dL and pravastatin -33.6 mg/dL, 31% vs 21% reduction in LDL-C,
respectively, p < 0.001). As pleased they are with the results, both companies
look forward to further analysis of the data. The Full Research Report on Eli
Lilly & Co. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Consider Wall Street Source

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Joe Thomas


Main: +1-310-496-8071 (North America)

SOURCE  Wall Street Source

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.